Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease.
Clin Chem Lab Med
; 49(1): 93-7, 2011 Jan.
Article
en En
| MEDLINE
| ID: mdl-21077793
ABSTRACT
BACKGROUND:
Evidence suggests that zinc-α(2)-glycoprotein (ZAG) might serve as a biomarker for human metabolic alterations. We measured serum ZAG in patients with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, and examined its association with clinical, biochemical, and histological phenotypes.METHODS:
Serum ZAG was determined using ELISA in 90 patients with biopsy-proven NAFLD and 81 controls.RESULTS:
Serum ZAG concentrations did not differ in patients with NAFLD (median 61 µg/mL; interquartile range 56-73 µg/mL) compared with healthy controls (median 66 µg/mL; interquartile range 56-78 µg/mL, Mann-Whitney U-test, p=NS). However, among patients with NAFLD serum ZAG concentrations were significantly higher in males and in those with the metabolic syndrome. After stepwise linear regression analysis, serum ZAG concentrations were the only independent predictor of the number of metabolic syndrome components in patients with NAFLD (ß=0.22; t=2.001, p<0.05).CONCLUSIONS:
In summary, the hypothesis of an association between NAFLD and serum ZAG concentrations is not supported by the present results. However, ZAG remains an interesting molecule for further research in the field of human metabolic disorders.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proteínas de Plasma Seminal
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2011
Tipo del documento:
Article